Actualités Moberg Pharma Ab (publ) - 0P48 | Actions London Stock Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing

OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing PR Newswire STOCKHOLM, Nov. 16, 2020...

Extended fiscal year July 2019 - December 2020 Interim report July - September 2020

Extended fiscal year July 2019 - December 2020 Interim report July - September 2020 PR Newswire STOCKHOLM, Nov. 10, 2020 STOCKHOLM, Nov. 10, 2020...

Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million

Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million PR Newswire STOCKHOLM, Nov. 6, 2020 STOCKHOLM, Nov. 6...

Moberg Pharma intends to distribute and separately list BupiZenge® (BUPI)

Moberg Pharma intends to distribute and separately list BupiZenge® (BUPI) PR Newswire STOCKHOLM, Nov. 6, 2020 STOCKHOLM, Nov. 6, 2020...

Moberg Pharma intends to submit a registration application in Europe in 2021

Moberg Pharma intends to submit a registration application in Europe in 2021 PR Newswire STOCKHOLM, Oct. 14, 2020 STOCKHOLM, Oct. 14, 2020...

Moberg Pharma intends to submit a registration application in Europe in 2021

Moberg Pharma intends to submit a registration application in Europe in 2021 PR Newswire STOCKHOLM, Oct. 14, 2020 STOCKHOLM, Oct. 14, 2020...

Moberg Pharma: Interim report April - June 2020

Moberg Pharma: Interim report April - June 2020 PR Newswire STOCKHOLM, Aug. 11, 2020 STOCKHOLM, Aug. 11, 2020 /PRNewswire/ -- The Primary...

Appointment of Chief Medical Officer at Moberg Pharma

Appointment of Chief Medical Officer at Moberg Pharma PR Newswire STOCKHOLM, July 30, 2020 STOCKHOLM, July 30, 2020 /PRNewswire/ -- Moberg Pharma...

New number of Shares and Votes in Moberg Pharma AB (publ)

New number of Shares and Votes in Moberg Pharma AB (publ) PR Newswire STOCKHOLM, June 30, 2020 STOCKHOLM, June 30, 2020 /PRNewswire/ -- During...

Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study

Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study PR Newswire STOCKHOLM, June 25, 2020 STOCKHOLM, June 25, 2020 /PRNewswire/...

Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study

Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study PR Newswire STOCKHOLM, June 25, 2020 STOCKHOLM, June 25, 2020 /PRNewswire/...

New Number of Shares and Votes in Moberg Pharma AB (publ)

New Number of Shares and Votes in Moberg Pharma AB (publ) PR Newswire STOCKHOLM, May 29, 2020 STOCKHOLM, May 29, 2020 /PRNewswire/ -- Moberg...

Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020

Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020 PR Newswire STOCKHOLM, May 12, 2020 STOCKHOLM, May 12, 2020...

Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to Teleconference

Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to Teleconference PR Newswire STOCKHOLM, May 5...

Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)

Notice of Extraordinary General Meeting in Moberg Pharma AB (publ) PR Newswire STOCKHOLM, March 27, 2020 STOCKHOLM, March 27, 2020 /PRNewswire/...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Moberg Pharma Ab (publ) (0P48)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

0P48 Actualités

OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing

Extended fiscal year July 2019 - December 2020 Interim report July - September 2020

Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million

Moberg Pharma intends to distribute and separately list BupiZenge® (BUPI)

Moberg Pharma intends to submit a registration application in Europe in 2021

Moberg Pharma intends to submit a registration application in Europe in 2021

Moberg Pharma: Interim report April - June 2020

Appointment of Chief Medical Officer at Moberg Pharma

New number of Shares and Votes in Moberg Pharma AB (publ)

Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study

Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study

New Number of Shares and Votes in Moberg Pharma AB (publ)

Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020

Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to Teleconference

Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Moberg Pharma Ab (publ) (0P48) Actualités

Moberg Pharma Ab (publ) (0P48)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

0P48 Actualités

OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing

Extended fiscal year July 2019 - December 2020 Interim report July - September 2020

Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million

Moberg Pharma intends to distribute and separately list BupiZenge® (BUPI)

Moberg Pharma intends to submit a registration application in Europe in 2021

Moberg Pharma intends to submit a registration application in Europe in 2021

Moberg Pharma: Interim report April - June 2020

Appointment of Chief Medical Officer at Moberg Pharma

New number of Shares and Votes in Moberg Pharma AB (publ)

Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study

Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study

New Number of Shares and Votes in Moberg Pharma AB (publ)

Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020

Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to Teleconference

Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application